Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition
Daniel R. Principe, Jeffrey H. Becker, Anastasia E. Metropulos, Alejandra M. Marinelarena, Thao D. Pham, Alexandre F. Aissa, Hidayatullah G. Munshi
This paper shows that BET inhibitors can overcome resistance to KRASG12D inhibitor MRTX1133 in pancreatic cancer by reversing pro-survival signaling.
Molecular Cancer Therapeutics · Jan 12, 2026Peer-reviewedCancer Biology